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The rapid and irrepressible increase in antimicrobial resistance of pathogenic bacteria that has been observed
over the last two decades is widely accepted to be one of the major problems of human medicine today.
Several aspects of this situation are especially worrying. There are resistance mechanisms that eliminate
the use of last-choice antibiotics in the treatment of various kinds of infection. Many resistance
mechanisms that emerge and spread in bacterial populations are those of wide activity spectra, which
compromise all or a majority of drugs belonging to a given therapeutic group. Some mechanisms of great
clinical importance require specific detection procedures, as they may not confer clear resistance in vitro
on the basis of the interpretive criteria used in standard susceptibility testing. Finally, multiple
mechanisms affecting the same and/or different groups of antimicrobials coexist and are even co-selected in
more and more strains of pathogenic bacteria. The variety of b-lactamases with wide spectra of substrate
specificity illustrates very well all the phenomena mentioned above. Being able to hydrolyze the majority of
b-lactams that are currently in use, together they constitute the most important resistance mechanism
of Gram-negative rods. Three major groups of these enzymes are usually distinguished, class C
cephalosporinases (AmpC), extended-spectrum b-lactamases (ESBLs) and different types of b-lactamases
with carbapenemase activity, of which the so-called class B metallo-b-lactamases (MBLs) are of the greatest
concern. This review is focused on various aspects of the evolution and epidemiology of ESBLs; it does not
cover the problems of ESBL detection and clinical relevance of infections caused by ESBL-producing
organisms.
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ESBL EVOLUTION
A general definition of extended-spectrum b-lactamases
(ESBLs) consists of several elements [1]. ESBLs are active site
serine Ambler’s class A or class D b-lactamases [2,3], which are
able to hydrolyze oxyimino-b-lactam compounds at a rate that
is equal to or higher than 10% of that for benzylpenicillin. They
demonstrate good activity against broad-spectrum penicillins
and cephalosporins, and are inhibited by site-directed b-lacta-
mase inhibitors [1]. In the b-lactamase functional classification
scheme by Bush, Jacoby and Medeiros, ESBLs are located in
two subgroups of group 2, namely subgroups 2be (extended-
spectrum b-lactamases; Ambler’s class A enzymes) and 2d
(cloxacillin-hydrolyzing b-lactamases; Ambler’s class D ESBLs)
[1].
For several reasons, ESBLs pose a serious clinical problem.
The first of these arises directly from their wide substrate
specificity, which in general includes almost all penicillins,
cephalosporins (except cephamycins) and monobactams
[1,4]. The second is the fact that ESBL producers frequently
appear susceptible in vitro to some ESBL substrates [5–7],
which, among other reasons, is due to high quantitative differ-
ences in the activity of certain ESBL variants against particular
compounds [1,4,8–11]. However, because such drugs were
often found to be non-efficacious in vivo [12–16], it is broadly
accepted today that, aside from those identified in urinary tract
infections, ESBL-producing isolates should, by definition, be
reported as resistant to all ESBL substrates [4]. This creates a real
challenge for clinical microbiology laboratories, which should
precisely detect the ESBL phenotype [6,17–24]. Finally, the
third important aspect of the presence of ESBLs results from
their complex and dynamic evolution and epidemiology.
ESBLs are usually described as acquired b-lactamases that are
encoded mostly by plasmid-located genes [4,25]. As such, they
are a very recent evolutionary development; the first clinical
isolates expressing acquired ESBLs were identified in Germany
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in 1983 [26,27]. In 1985 the first nosocomial outbreaks caused
by ESBL producers started to occur in France [28], and then in
the USA at the end of the 1980s and the beginning of the 1990s
[8,13,29–31]. It is, however, noteworthy that some species-
specific b-lactamases are biochemically indistinguishable from
ESBLs and are classified into the Bush subgroup 2be too [1],
such as OXY enzymes of Klebsiella oxytoca [32,33] or CME
b-lactamases of Chryseobacterium meningosepticum [34,35].
Moreover, certain species-specific Bush subgroup 2e cephalos-
porinases [1], e.g. CepA of Bacteroides fragilis [36], CblA of
Bacteroides uniformis [37] or L2 of Stenotrophomonas maltophilia
[38,39], differ from the 2be enzymes only by their rather poor
activity against penicillins. Both the 2be and 2e species-specific
b-lactamases reveal clear structural homologies to some types of
classical ESBLs [34,35,40–44]. All of these data indicate that the
model of a class A b-lactamase with a substrate-binding cavity
broad enough to interact with oxyimino-b-lactams is not, in
fact, so recent in bacterial evolution, and that some ESBLs could
inherit their principal characteristic from species-specific
ancestral b-lactamases.
The number of ESBL variants identified has been constantly
growing since 1983, demonstrating how rapid ESBL evolution
has been. More than 100 different natural ESBL variants are
known at present, and the list seems to be far from complete
(http://www.lahey.org/studies/webt.htm) [42–45]. They have
been classified into nine distinct structural/evolutionary
families based on comparisons of their deduced amino acid
sequences (families TEM, SHV, CTX-M, PER, VEB, GES,
TLA, BES and OXA). Major families are formed by TEM and
SHVenzymes, which include the first ESBL variants identified
[26–28,46,47], and which have remained the most prevalent
ESBL types, in terms of both variant numbers and numbers of
producer strain isolations (http://www.lahey.org/studies/
webt.htm). OXA enzymes, which are the only ESBLs of class
D [3], represent another relatively prevalent ESBL family
(http://www.lahey.org/studies/webt.htm). TEM, SHV and
OXA ESBLs are structural derivatives of acquired, so-called
broad-spectrum b-lactamases, such as TEM-1, TEM-2 and
SHV-1 (all Bush subgroup 2b), and OXA-2 and OXA-10
(subgroup 2d), respectively (http://www.lahey.org/studies/
webt.htm) [1,4,25,48]. Their deeper evolutionary origins are
unclear, with the exception of SHV enzymes, which most
probably evolved from the K2 variant of Klebsiella pneumoniae
species-specific b-lactamase [49]. The genealogy of the remain-
ing ESBL families is, in general, more mysterious; however, as
mentioned above, amino acid sequence comparisons have
revealed similarities of some of them to certain species-specific
b-lactamases from Bush subgroups 2be and 2e. These homo-
logies range from 30–40% up to 99%, which indicates common
origins of the discerned clusters of enzymes and, in the case of a
very high homology value, even the direct descent of an ESBL
from a species-specific enzyme. A good example is the CTX-M
family, which has been rapidly growing in recent years (http://
www.lahey.org/studies/webt.htm) [50]; this groups ESBLs
related to b-lactamases of Kluyvera ascorbata (99% homology
with the CTX-M-2 variant), Klebsiella oxytoca, Citrobacter diver-
sus, Proteus vulgaris and Serratia fonticola [40,41,51]. On the other
hand, the minor ESBL families PER, VEB and TLA have been
found to be distantly related to each other and also to Bacteroides
fragilis CepA, Bacteroides uniformis CblA and Chryseobacterium
meningosepticum CME b-lactamases [34,35,42,43]. All these
observations lead to the conclusion that ESBL activity is
demonstrated by enzymes with substantial diversity in terms
of structure and evolutionary origins.
Most of what we know about ESBL evolution comes from
studies of TEM and SHVenzymes, which, as mentioned above,
are mainly structural mutants of TEM-1, TEM-2 and SHV-1
penicillinases, respectively. The prevalence of these b-lacta-
mases in nosocomial Enterobacteriaceae populations, reflected,
for example, by an ampicillin resistance rate of about 50% in
Escherichia coli [4], is one of the key factors responsible for the
wide spread of TEM and SHV ESBLs around the world.
Comparisons of nucleotide sequences of TEM and SHV ESBL
genes with those coding for their parental penicillinases have
revealed numerous point mutations, which cause amino acid
substitutions in a b-lactamase polypeptide. Many of these
substitutions have been found to affect enzyme structure and
activity in different ways, and were thoroughly discussed by
Knox in his review [52]. The most important are spectrum-
extending mutations (position 164 in TEMs, 179 in SHVs and
238 in both), which, by enlarging the b-lactam-binding site,
make enough room for enzyme interactions with compounds
possessing bulky oxyimino side-chains. Causing serious struc-
tural alterations, these mutations diminish the overall enzymatic
activity of a b-lactamase when compared to parental enzymes
[48,52]. Other substitutions (104 in TEMs and 240 in TEMs
and SHVs) enhance b-lactamase interactions with oxyimino
side-chains of specific compounds (ceftazidime and aztreonam)
[52]. There is a mutation (237 in TEMs) which modulates
b-lactamase activity by reducing it against certain b-lactams
(ceftazidime and aztreonam) while increasing it towards others
(cefotaxime and cephalothin) [53]. Another substitution (182 in
TEMs) serves as an intragenic suppressor that compensates for
b-lactamase structural defects resulting from spectrum-extend-
ing substitutions [54]. In some TEM and SHVenzymes, ESBL-
type mutations have been identified together with those that
determine b-lactamase resistance to b-lactam inhibitors, inhi-
bitor resistance-type substitutions (positions 69, 130, 275, 276)
[52,55–57]. Finally, not only substitutions but also amino acid
insertions or deletions have been found either to be responsible
for or to possibly contribute to ESBL activity [58,59]. What is
noteworthy is that a combination of mutations with defined
roles does not have to result in a simply additive effect on
b-lactamase activity. TEM-52 has been shown to hydrolyze
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moxalactam and cefotetan, which is unlikely be attributable
to any of its substitutions alone (104, 182, 238) [60], whereas
in SHV-10 the IR-specific substitution (130) is strongly
detrimental to ESBL activity [55].
Among all the changes identified in TEM and SHV ESBLs,
there are also single amino acid substitutions, which are con-
sidered to be neutral (e.g. position 21 in TEMs [61]); however,
it is possible that some of these need a specific context of other
mutations to reveal their cryptic role [53,54]. Neutral or nearly
neutral mutations do not undergo strong, if any, selective
constraints, and therefore their repeated selection under strictly
defined pressure is less likely than that of mutations which turn
out to be profitable in a given environment. In general, this is
the case with silent mutations too, which can also be found in
ESBL genes when compared to each other. Some of the neutral
or nearly neutral substitutions and at least the majority of silent
mutations observed were inherited by TEM and SHV ESBL
genes from different variants of their parental penicillinase genes
[62–65] and constitute specific markers of diverse genealogic
lineages of ESBL genes. Analysis of these mutations is very
useful in evolutionary as well as epidemiologic investigations
within particular ESBL families [64,66]. This has been demon-
strated, for example, in studies of genes coding for TEM-12 and
TEM-26 ESBLs (blaTEM-12 and blaTEM-26) in clinical isolates
from British, French and US hospitals. Specific distribution of
silent mutations in these genes has excluded the possibility of the
transfer of producer strains from the USA to the UK and France,
and clearly indicates events of convergent evolution [67–70].
Some ESBL variants have evolved and may still evolve
directly from broad-spectrum b-lactamases, due to single spec-
trum-extending mutations [47,71–73]; however, the vast
majority of them have emerged by the stepwise acquisition
of different mutations by pre-existing ESBLs. This process was
very well documented by the work of Bradford et al., who
identified two ESBL genes differing by one nucleotide sub-
stitution in a single Klebsiella pneumoniae isolate. The blaTEM-10
gene probably appeared as a result of duplication of blaTEM-12,
which was followed by the acquisition of an additional mutation
[31]. The comparison of genes coding for different TEM ESBL
variants in Polish hospitals strongly suggests that, in a sequence
of single genetic changes, blaTEM-48 gave rise to blaTEM-47 and
blaTEM-49, and then blaTEM-68 evolved from blaTEM-47 [57,66].
The selection pressure that drives ESBL evolution has usually
been attributed to the intense use of oxyimino-cephalosporins,
mainly ‘third-generation’ cephalosporins [48]. This was well
documented in a study conducted in 1993–94 in a hospital in
Cleveland, where the frequency of ESBL-producing Klebsiella
pneumoniae isolates was positively correlated with the use of
ceftazidime and negatively with that of piperacillin–tazobactam,
to which the isolates were susceptible [14]. There also exists an
interesting observation from Japan, where in the 1990s ESBL-
producing organisms were sporadically identified and usually
expressed the so-called Toho b-lactamases from the CTX-M
family [74–77]. It is possible that the low incidence of ESBLs in
Japan has been at least partially due to the intense use of
cephamycins and carbapenems in this country [74]. As ESBLs
often demonstrate selective preferences regarding different
oxyimino-b-lactams, selection of a particular enzyme variant
in a given center has been frequently attributed to the specific
profile of antibiotic use. This was, for example, the case with
a high prevalence of the TEM-26 ceftazidime-hydrolyzing
b-lactamase in several US hospitals in 1988–92, into which
ceftazidime was introduced in high amounts at that time
[8,13,29]. In 1996–97, the CTX-M-3 cefotaxime-hydrolyzing
ESBL was found to predominate in a hospital in Warsaw, where
the consumption of ceftriaxone and cefotaxime exceeded that
of ceftazidime by around four times [78]. However, such a
correlation has not always been observed, as is the case in a study
performed in a Chicago hospital in 1990–91, in which the
TEM-10 ceftazidime-hydrolyzing b-lactamase was identified as
the most prevalent ESBL variant. Its high prevalence coincided
with the introduction of ceftazidime to the hospital, but because
the use of cefotaxime was much higher at that time, a greater
selective potential of ceftazidime was suggested [31].
In recent papers by Bla´zquez et al., a wider view of the
problem has been proposed, according to which ESBLs evolve
under the constant or fluctuating pressure of various b-lactam
antibiotics, including diverse oxyimino-compounds as well as
penicillins and early-generation cephalosporins [53,79]. The
authors postulate that such conditions may be responsible for
the selection of TEM enzymes carrying the modulating sub-
stitution at position 237, which converts ESBL variants of
highly ‘asymmetric’ substrate preferences into those with much
more balanced activity [53,80]. This hypothesis probably con-
tains also one of the main explanations for the fact that only a
fraction of all possible spectrum-extending mutations have been
selected under natural conditions when compared to laboratory
mutant studies [81–84]. Structural defects resulting from some
spectrum-extending mutations appear to diminish b-lactamase
activity too far against, for example, aminopenicillins [79]. It
could also be suggested that pressure of the use of non-oxyi-
mino-b-lactams may be responsible for the selection of muta-
tion combinations that further extend ESBL activity, as in
TEM-52 towards moxalactam [60], or for the selection of
so-called complex mutant enzymes, which combine ESBL-
and IR-type mutations [55–57]. Out of three such enzymes
identified to date under natural conditions, two variants, TEM-
50 and TEM-68, have been found to retain both activities at
significant levels [56,57].
The concept of multi-b-lactam pressure does not explain all
the phenomena that are observed in ESBL evolution and
epidemiology. ESBLs characterised by highly selective substrate
preferences are being selected [50,68,80] and may remain
prevalent at the level of a single medical center or on a wider
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geographic scale [78,85,86]. Moreover, as Bla´zquez et al. point
out, enzyme variants with ‘rare’ spectrum-extending mutations
may also be sporadically selected. By way of example, it could be
the case that the mutation in position 179, which, although
never found in natural TEM ESBLs, is identified in some SHVs
[79,87–89]. This may be due to reduced competition that
occurs in specific niches of complex nosocomial environments
[79] or unique profiles of antibiotic use in particular hospitals or
hospital wards. The ‘modulating tendency’ of multi-b-lactam
pressure may also be limited by the fact that ESBLs often appear
efficacious in vivo against their weaker substrates [12–15].
Nevertheless, the multi-b-lactam pressure hypothesis seems
to be of great importance.
The strong selective pressure of the use of b-lactam drugs
exerted on ESBL producer strains operates not only on ESBL
gene coding regions, but also on their promoters, copy number
and other genes. Such changes may significantly affect the
b-lactam resistance of strains by increasing its level, expanding
it for non-ESBL substrates, and/or compromising the activity of
b-lactamase inhibitors. Several reports have documented the
selection of strains that hyperproduced ESBLs due to various
genetic changes such as promoter up-mutations, insertion of
transposable elements close to the promoter region, or multi-
plication of the ESBL gene copy number [90–93]. Other work
has demonstrated the emergence of strains expressing two
ESBLs of different types [68,85,86,94,95]. In Argentina and
Poland, where cefotaxime-hydrolyzing CTX-M ESBLs are
widespread, the ‘double-ESBL’ isolates producing such an
enzyme and an ESBL with a much stronger activity against
ceftazidime have been found [85,86,95]. Owing to mutations in
genes coding for porin proteins, ESBL producer strains fre-
quently show reduced permeability for antibiotics, and this is
usually manifested by cefoxitin resistance in Klebsiella pneumo-
niae strains [96–98]. In recent years, ESBLs have become more
and more prevalent in species characterised by inducible class C
cephalosporinases (AmpC), such as Enterobacter spp., Citrobacter
freundii or Serratia marcescens, which frequently segregate mutants
with high-level constitutive production of AmpC enzymes
[4,48,78,95,99,100]. Strains that are both ESBL producers
and AmpC derepressed mutants have been already identified
in several studies [86,101,102], despite the masking of the ESBL
phenotype by the inhibitor resistance of AmpC b-lactamases.
ESBL-producing isolates are frequently resistant to other
kinds of antimicrobials, including aminoglycosides, quinolones
and co-trimoxazole [13,28,31,78,89,103]. What is especially
frustrating is that genes coding for ESBLs and, for example,
aminoglycoside-modifying enzymes (AMEs) often reside
within the same conjugative plasmids and therefore are trans-
mitted together from one strain to another [78,104,105]. This
means that resistance to two different kinds of drugs may be co-
selected by the use of either one. Bell and Turnidge demon-
strated that, in 1998–99 in Western Pacific countries and South
Africa, the frequency of resistance in ESBL-producing Enter-
obacter cloacae to gentamicin, ciprofloxacin and co-trimoxazole
could reach values of approximately 65%, 60% and 20%,
respectively [100].
ESBL EP IDEMIOLOGY
ESBL epidemiology should be considered at different levels,
namely the level of a single patient, of a single medical institu-
tion, and on a wider geographic scale, and at each of these it
strongly depends on evolutionary phenomena that occur in
ESBL-producing strains. A very informative example of such an
overlap between evolutionary and epidemiologic problems in
the course of infection of a single patient was reported by
Rasheed et al., who followed the 3-month progression of an
Escherichia coli infection of a child with several bacteremia
episodes. Analysis of multiple isolates of the organism which
were collected over time revealed a very complex view of both
the linear and radiative evolution of an originally single bacterial
strain, which coincided with intense antimicrobial therapy. It
involved such events as acquisition of the SHV-1-encoding
gene, hyperproduction of the enzyme, emergence of SHV-8
ESBL by a single point mutation in blaSHV-1, porin alterations,
and acquisition of resistance to other antimicrobials [89]. On the
other hand, studies by Marchandin et al. have demonstrated the
interspecies dissemination of an ESBL gene-carrying plasmid in
a single multibacterial infection/colonisation case [106,107]. In
one of these, the horizontal transfer of a plasmid with the TEM-
24-encoding gene was observed between strains of Enterobacter
aerogenes, Escherichia coli, Proteus mirabilis and Pseudomonas
aeruginosa [106].
ESBLs have been found in a wide range of Gram-negative
rods; however, the vast majority of strains expressing these
enzymes belong to the family Enterobacteriaceae [4,108–
110]. Numerous species of this family have already been
identified as hosts of ESBL expression, including organisms
of the so-called Enteric Group 137, with as yet no clear
taxonomic position [111]. Klebsiella pneumoniae seems to remain
the major ESBL producer; this is reflected both by its usually
outstanding contribution to all ESBL-expressing isolates iden-
tified in medical centers, and by the high incidence of ESBL
production in nosocomial populations of the species [4,108,
110,112]. Another very important organism is Escherichia coli,
which has a remarkably high representation among ESBL
producers circulating in hospital environments [4,108,112].
As mentioned above, ESBLs have become common over time
among species with inducible AmpC b-lactamases; this is well
illustrated by a recent Argentine survey, in which approximately
14% of all inducible AmpC strains studied were found to express
ESBLs [95]. What is also of note is the growing incidence of
ESBLs in Salmonella spp.; sporadic isolates of ESBL-producing
salmonellae or nosocomial outbreaks caused by these organisms
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have been already identified in numerous countries of Latin
America, Africa, Europe and Asia [113–115]. Non-Enterobac-
teriaceae ESBL producers are much rarer, with Pseudomonas
aeruginosa being the most important among them [116]. This
organism is a frequent host of OXA-type ESBL expression
[73,117,118]; however, Pseudomonas aeruginosa isolates produ-
cing TEM, SHV and PER ESBLs have also been identified in
several countries [106,119–123]. PER b-lactamases have also
been found in Acinetobacter spp. [124,125] and in Alcaligenes
faecalis [126]. Finally, TEM-17 has been detected in Capnocy-
tophaga ochracea [127] and SHV-12 in Burkholderia cepacia [128].
ESBL-producing organisms are usually selected in hospitals
[4,108,129]; however, a number of reports from the USA and
France have documented the possibility of their emergence in
nursing home facilities [121,130,131]. Recent studies on the
appearance of Salmonella spp. strains with the acquired CMY-2
AmpC enzyme in livestock [132,133] have also demonstrated
the danger of selection of ESBL producers in such environ-
ments. The frequency of ESBL producers in a hospital depends
on many factors and may vary greatly; in a 1988–90 survey
conducted in 12 French centers, the incidence of ESBL-produ-
cing isolates in Klebsiella pneumoniae populations ranged from
0% to approximately 50% [112]. The distribution of ESBL-
expressing strains within a hospital is similar to that of other
drug-resistant organisms, and they are usually more prevalent in
wards in which patients with numerous infection risk factors are
hospitalised. These are mainly intensive care units (ICUs)
[14,99,102,112,134,135], surgical wards [112], pediatrics and
neonatology wards [57,92,93,112], rehabilitation units [99],
oncologic wards [8,112] and chronic-care facilities [29,136].
An ESBL variant (ESBL producer strain) may appear in a
center due to de novo selection, which may result in a novel
type of enzyme [17,57,60,89,130] or in one that has been
previously identified in another institution (convergent evolu-
tion) [67–69,137]. It may also be imported by a patient from
another center, even though that may be located in another city
or country [31,57,138–141]. Once selected, the ESBL variant
may spread in the center by different means, including clonal
dissemination of the producer strain [14,92,93,142,143] or
horizontal transmission of the ESBL gene-carrying plasmid
among non-related strains [29,144]. A growing number of
ESBL outbreaks have recently been attributed to concurrent
plasmid transfer and clonal spread events [78,102,134]. In some
studies, the same ESBL-encoding gene has been identified in
different plasmids present in bacterial strains in a hospital, which
suggests either convergent evolution of the gene in a single
center or horizontal gene transfer among different plasmids
[31,78,131]. Indeed, some ESBL-encoding genes are located
within transposons or integrons, which strongly facilitates such
a transfer [42,45,70,118,145].
ESBL outbreaks may be large. In an approximately 500-bed
general hospital in New York, 165 patients were infected or
colonised by TEM-26-producing Klebsiella pneumoniae over a
19-month period at the beginning of the 1990s [13,30]. In
1993–94, 148 ESBL-producing Klebsiella pneumoniae isolates
were recovered from patients of an approximately 900-bed
hospital in Cleveland [14]. An approximately 1000-bed hospital
in Barcelona reported a figure of 145 patients infected or
colonised with ESBL-producing Klebsiella pneumoniae between
May 1993 and June 1995 [143]. ESBL outbreaks have also often
occurred, as was revealed in a study performed by Babini et al.
on ESBL-producing klebsiellae from ICUs of 13 European
hospitals in 1994 and 1997–98. Sixty-five per cent of the 1994
isolates and 69% of the 1997–98 isolates represented clonal
outbreak strains, and these were identified in nine of the ICUs
involved in the analysis [146]. The lower digestive tract of
colonised patients has been recognised as the major source of
ESBL-producing organisms [16], and their cross-transmission
among patients has been attributed to hands of medical per-
sonnel [16,92]. Some ESBL outbreaks have been revealed to
result from contamination of various diagnostics supplies, such
as thermometers [147], or gel used in ultrasonography [148].
An ESBL gene-carrying plasmid, an ESBL-producing strain
and even an ESBL outbreak may persist in a medical center over
a prolonged period. A family of related plasmid molecules
containing blaSHV-5 was identified in Enterobacteriaceae isolates
collected in a hospital in Albany between 1993 and 1999 [149].
In the aforementioned study of klebsiellae from ICUs of 13
European centers, nine ESBL-producing strains were observed
both in 1994 and 1997–98; moreover, three of these caused
permanent outbreaks [146]. Recently, Coque et al. have
reported results of an analysis of all ESBL-expressing Klebsiella
pneumoniae isolates collected in a hospital in Madrid over a
period of 11 years (1989–99). They have found that the blaTEM-
69-carrying plasmid was present in that population between
1995 and 1999, and that two different ESBL-producing strains
circulated in the hospital for 2 and 5 years, respectively. Inter-
estingly, this study has also documented the opposite phenom-
enon, which is a rapid turnover of ESBL producers in a medical
center. The two strains mentioned above were the only ones out
of 28 ESBL-expressing Klebsiella pneumoniae strains identified
that persisted for longer periods in the hospital [150].
Dynamic evolution is one of the main reasons why numerous
ESBL variants and producer strains exist in a center at the same
time. By the end of 1988, five different TEM ESBLs (TEM-5,
TEM-8, TEM-12, TEM-16 and TEM-24) had been identified
in the Klebsiella pneumoniae population in a hospital in
Clermont-Ferrand [151]. Three ESBL variants of different
families (TEM-10, TEM-26 and SHV-7) coexisted in Enter-
obacteriaceae strains of a hospital in New York in 1993 [130]. In
1996–97, in all, 22 CTX-M-3 or SHV-type ESBL-producing
strains of seven Enterobacteriaceae species (identified as RAPD
types) were distinguished in a hospital in Warsaw [78]. But pro-
bably the highest diversity of ESBLs and ESBL producers ever
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described in a single center was observed by Essack et al. in the
1996 Klebsiella pneumoniae population from a hospital in
Durban. Nine distinct strains were discerned among 13 ESBL-
producing Klebsiella pneumoniae isolates collected at the time,
and these were found to express many combinations out of
three TEM and six SHV b-lactamases, including different
ESBL variants (TEM-53, TEM-63, SHV-2, SHV-5, SHV-20,
SHV-22) [94].
One of the most intriguing issues of wider-scale ESBL
epidemiology is the frequency of ESBL producers in larger
geographic regions. This is very difficult to estimate, for a
variety of reasons; one of these arises from high variations in
ESBL incidence among different hospitals, which means that
the selection of centers for survey studies strongly influences the
mean data obtained [112]. It should also be considered that, due
to the dynamics of ESBL epidemiology, survey results might
describe a transient situation, characteristic for a given region
only at a certain point in time [99]. However, such studies have
been undertaken and give us some insights into the problem
concerning the global spread of ESBLs. Recent data from the
SENTRY Antimicrobial Surveillance Program, performed on
Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis and Salmo-
nella spp. isolates collected in 1997–99 from all over the world,
showed that ESBL frequency in Klebsiella pneumoniae may
account for about 45% in Latin America, 25% in the Western
Pacific, 23% in Europe and 8% in the USA [103]. The very
high incidence of ESBL production in Latin America has also
been observed in a SENTRY study for this region, in which
40.5% of Klebsiella pneumoniae isolates collected were found to
be ESBL positive [110]. In a 1994 survey carried out on
klebsiellae from 35 ICUs in 10 countries of western and
southern Europe, ESBLs were identified in 22.8% of all isolates
analyzed and in 28.6% of Klebsiella pneumoniae isolates
[152]. Similar data, with ESBL incidence standing at 25.4%
of all klebsiellae, was obtained in a follow-up study in 1997–98
[153].
On a single-country scale, the frequency of ESBL production
has been investigated in France since the mid-1980s, and the
results of two out of several surveys performed in the country
will be discussed here. In a 1988–90 study of b-lactam resistance
in 12 university hospitals, ESBL producers comprised 13.3% of
Klebsiella pneumoniae isolates and 1.5% of all Enterobacteriaceae
isolates; however, it was this study in which the aforementioned
high variations between hospitals were observed [112]. In 1998,
a similar survey was performed involving 14 hospitals from 11
regions of France, and ESBLs were detected in 9.5% of Klebsiella
pneumoniae isolates and 3.2% of all Enterobacteriaceae isolates.
Strikingly, the highest incidence of ESBLs was observed in
Enterobacter aerogenes (53.5%); however, this was due to the
intense multicenter spread of a single clone of this organism,
which may have been a transient epidemiologic phenomenon
[99]. In 1999, an ESBL survey was performed in 28 hospitals in
South Korea and revealed a frequency of 18.1% ESBL producers
among Klebsiella pneumoniae isolates [154].
It was observed in the 1980s that the same ESBL variant
might be present in several or even many different medical
institutions. Such a spread of an ESBL variant can occur due to
the dissemination of a single clone of an ESBL-producing
organism in numerous centers of a region, which seems to
strongly indicate frequent occurrences of strain transmission
from one center to another. This was well documented in
France, with an SHV-4-producing Klebsiella pneumoniae clone
being found in 14 hospitals by the end of 1988 [140], and the
previously mentioned TEM-24-producing Enterobacter aerogenes
clone spreading into 21 hospitals by 1997 [141]. Recently, a
single clone of CTX-M-type ESBL-producing Salmonella typhi-
murium has been identified in Russia, Hungary and Greece
[115]. In other cases, the presence of a single ESBL variant in
different centers may be attributed mostly to the dissemination
of an ESBL gene-carrying plasmid; however, this also suggests
an important role for the transmission of producer strains
between institutions. For example, plasmid transfer was revealed
to be responsible for the spread of TEM-3 in France, identified
in strains of 10 different species in 26 hospitals by 1989
[155,156], and of CTX-M-3 in Poland, found in eight species
in 15 hospitals by 2000 [86]. Finally, convergent evolution may
also lead to a wide geographic representation of an ESBL variant
[67–70], and this has probably been a major factor in the
‘international career’ of SHV-5, despite documented cases of
its importation to one country from another [138]. SHV-5 has
been found in almost every country in which ESBLs have ever
been studied down to the molecular level [57,64,95,97,
134,148,157–165], and in some of these, e.g. in Poland, its
gene was identified in a wide variety of plasmids in bacterial
isolates from numerous hospitals [57,78,135]. The described
phenomena, alone or in combination with each other, may lead
to the high prevalence of certain ESBL variants in particular
regions or countries. The French 1998 ESBL survey revealed
that TEM-24 was expressed by 51.9%, and TEM-3 by 35.4%, of
all ESBL-producing isolates included in the study, which means
that these two enzymes are mainly responsible for the clear
predominance of TEMs among all ESBLs that can be currently
observed in France [99].
CONCLUSIONS
Less than 20 years after the first identification, ESBL-producing
Enterobacteriaceae have become common microorganisms in
medical institutions of many countries and larger geographic
regions. Together with methicillin-resistant staphylococci, van-
comycin-resistant enterococci and some other types of patho-
gens, they now make a major contribution to the serious clinical
problem created by nosocomial infections with very limited
therapeutic options. Various factors of different kinds facilitate
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their spread, including the diversity of parental b-lactamases in
ESBL evolution, the worldwide prevalence of their specific
types, the relative ease of emergence of an ESBL, the ‘mobility’
of ESBL genes and, finally, the strong selective pressure of
antibiotic use. The very rapid evolution of ESBLs seems to run
in several directions, such as increased activity, its modulation or
further extension, and, together with other evolutionary
changes observed in ESBL producer strains, it is leading to
an increase in the level and an expansion of the spectrum of their
resistance phenotypes. In recent years, ESBLs have greatly
widened the range of their host species, and the growing
incidence of ESBLs in Salmonella spp. demonstrates the danger
of their spread among pathogens circulating in livestock and the
community. ESBL outbreaks are usually complicated and diffi-
cult to eradicate, and frequently evolve into complex endemic
situations characterised by a high variety of producer strains
expressing multiple b-lactamase combinations at a single
center. The insufficiently monitored movement of infected
or colonised patients between different medical institutions
often causes a very wide geographic spread of particular ESBL
variants and their producer strains. All these factors taken
together illustrate that ESBL epidemiology today is very
dynamic, and the prediction of its consequences in the future
is difficult.
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